Isoniazid-resistant, rifampin-susceptible tuberculosis (INH-R TB) is the most common 4 form of drug resistance, and is associated with significant rates of failure, relapse, and 5 acquired rifampin resistance if treated with first-line anti-TB drugs. 6
The aim of the study was to compare success, mortality and acquired rifampin resistance 7 with:1) different durations of rifampin, ethambutol and pyrazinamide (REZ); 2) 8 fluoroquinolone plus 6 months or more of REZ; 3) streptomycin plus a core regimen of 9 REZ, in INH-R pulmonary TB. Variables from each dataset were mapped to a common set of variables for all patients, and 35 to verify, the clinical characteristics of each study population were compared with 36 description of these characteristics in the published papers. 37 38
Quality assessment 39
As the studies in the IPD were mainly observational, we assessed bias and quality using 40 eight items. Two were critical (sampling method and outcome definition) and six were 41 important criteria (participation rate, attrition rate and completeness of information for age, 1 HIV status, cavity at chest-x ray and smear). 2
Studies of high quality met both critical criteria and at least four of the six important 3 criteria (see supplement table S1E -for quality criteria and assessments). Studies of 4 moderate quality met one of the two critical parameters and at least four of the important 5 criteria, or two critical parameters and at least three of the important criteria. Remaining 6 studies were considered of low quality. We assessed overall quality of the evidence from 7 this IPD following GRADE criteria. For individualized regimens, the actual duration was estimated from dates when drugs were 24 started and stopped. For standardized regimens, or randomized trials, if actual treatment 25 duration was not available, the planned duration was used. For the outcome of death, which 26 could occur at any time during treatment, duration could not be analyzed, since the duration 27 of therapy was determined by the outcome. However, the analysis of mortality was 28 restricted to the same data sets used for the analysis of treatment success -ie studies in 29 which the regimens used and durations of regimens corresponded to the study questions. 30 31
We used propensity score matching 23 (Caliper method with difference of 0·02 allowed, 1:1 32 matching with replacement) based on age, gender, HIV co-infection, AFB smear, past 33 history of TB treatment and resistance to other first line drugs, if the drug was used. 34
We used a random effects (random intercept and random slope for matched pairs) model 35 (using Proc GLIMMIX in SAS) to estimate adjusted odds ratios (aOR) and 95% confidence 36 intervals (CI) of the three outcomes. Risk differences were calculated with fixed effects 37 generalized linear models with identity link, adjusted for the propensity score. To test for 38 heterogeneity of effect across studies, we used a generalized linear mixed model with an 39 simulation-based approach specifically for individual patients data meta-analysis, to 40 calculate the I2 statistic.
41 42
For all outcomes and all questions, we performed the following sensitivity analyses: (i) 1 restricting to the sub-group of patients who had not received isoniazid; (ii) restricting to the 2 sub-group with cavitation on chest radiography; (iii) stratified by country income level 3 (high, or low-middle); and, for the fluoroquinolone questions: (iv) restricting to patients 4 who received levofloxacin or moxifloxacin. All analysis was performed using SAS, version 5 9·4 (SAS Institute, Carey, N.C. To define isoniazid resistance, a critical concentration of 0·1 or 0·2 mcg/ml was used by 21 1 centers, and 0·25mcg/ml, or either 0·2 or 1·0 mcg/ml in single studies. The outcome 2 definitions and drug dosages given were in accordance with WHO guidelines (tables S1c 3 and S1d). Daily regimens were used in all but one study. 50 Therapy was directly supervised 4 throughout treatment for 2018 patients in 14 centres. Actual duration of therapy was known 5 in 16 studies (2422 participants, of whom duration was not known in 15), and planned 6 duration in the remaining 7 studies (1513 persons). Overall, 345 of all 3923 patients (9%) 7
were lost, or transferred out without known outcome, or stopped therapy for patient 8 decision. In 19 of 23 studies recurrence/relapse was measured, during follow-up that 9 exceeded one year in about two-thirds of patients; only two of these centers 34,39 used 10 molecular methods to identify reinfection. Quality assessments are summarized in appendix 11 table S1E; based on the criteria selected, the quality was judged low in one study, moderate 12 in four, and high in the remainder. 13
Results of testing for heterogeneity (i.e. estimated I squared, using a generalized linear 14 mixed model adjusted for the same confounding factors used in the propensity score 15 matching) are presented for each analysis in tables 1-4. In general, for analyses in which I 16 squared was estimable, the heterogeneity was low (<50%). 17
The analyzed population included only 37 children, 119 patients with diabetes mellitus, and 18 249 with HIV infection with or without antiretroviral treatment; these small numbers 19 precluded separate analyses, for any study questions, within these sub-groups. 20 21
Question 1: Duration of (H)REZ 22 23
As seen in table S3, patients receiving 6 months (H)REZ were older, more likely treated in 24 high income countries and less likely to be acid fast bacilli (AFB) smear-positive than 25 patients receiving more than 6 months (H)REZ. 26 27
As seen in table 1, odds of success were non-significantly higher with the six month 28 regimen (aOR 2·4; 95%CI 1·0; 5·5), and acquired resistance was non-significantly lower 29 (aOR 0·2; 95%CI 0·0; 1·7). When patients taking isoniazid (at usual doses) for at least one 30 month were excluded ( The 251 who received a FQ had significantly higher odds of treatment success than those 1 who did not, and non-significantly lower odds of acquired resistance to rifampin and of 2 mortality (table 2) . Estimates of effect were similar, and non-significant, when restricting 3 the analysis to the subgroup of patients who did not receive isoniazid, or patients who 4 received only later generation FQ. 5 6
Only 118 patients received a FQ together with 6 or more months of rifampin and 7 ethambutol, and 1-3 months of pyrazinamide, of whom 105 received a later generation FQ. 8
As seen in table S5, they were substantially older, and less likely to have cavitation or AFB 9 positive smears than the comparison group. In these patients, use of a FQ was associated 10 with non-significantly higher success, with similar results when restricting the analysis to 11 use of a later generation FQ ( Even though most studies were considered high quality, we considered that the risk of bias 5 was high, given that all but two were observational, and most provided individualized 6 treatment. Because relatively small numbers of patients received the regimens of interest, 7
estimates of effect were generally imprecise with wide confidence intervals. There were 8 also concerns over directness -for the findings of FQ to low-middle income settings, and 9
for the SM analyses to high income settings. Hence, overall the evidence from this IPD 10 should be considered of very low quality. 11 12
Discussion

13
We assembled a large set of individual data of patients with INH-R TB, mostly from 14 observational studies. occurred due to unmeasured differences in patient characteristics such as nutritional status. 7
As well treatment given at different centres may have been confounded with differences 8 between centres, such as resources available for patient support. To account for this, we 9 performed sensitivity analyses restricted to studies from high-income or low-middle 10 income countries only. For most of these analyses, estimates of effect were similar, but less 11 precise, due to fewer studies and patients included (tables S7 and S8). 12 13
Additional limitations were the small number of children, HIV-infected patients, and 14 patients with diabetes-limiting generalizability to these important groups of patients. Less 15 than half the studies reported acquired rifampin resistance during treatment; the resulting 16 smaller numbers limit our inferences for this outcome. The impact of treatment duration on 17 mortality could not be assessed as duration of therapy was truncated by death. A final 18 limitation was that adverse drug reactions could not be analyzed, as planned, because these 19 were not reported, or reported using widely varying definitions, methods of investigation, 20 and management. Non-standardized reporting of adverse events in the treatment of drug-21 resistant TB has been noted in other reviews of drug-resistant TB treatment. We conclude that, for the treatment of INH-R TB, addition of a FQ to a core regimen of 6 1 months of daily REZ provides optimal outcomes, although we could not define the best 2 FQ, nor the optimal duration of FQ nor pyrazinamide. Addition of isoniazid, and 3 prolongation of daily REZ beyond 6 months appear to provide no benefits. Addition of 4 streptomycin, and in particular the streptomycin-containing previously recommended 5 retreatment regimen, was associated with significantly worse treatment success. These 6 results, based on observational data, must be considered very low-quality evidence, and so 7 are insufficient to support strong treatment recommendations. However, they do strongly 8 support the conduct of randomized trials to identify the optimal regimen for this important 9
and common form of drug-resistant TB. there is access only to Xpert ® MTB/Rif, INH-R TB will be missed, and treated with 4 standard regimens. Despite the frequent occurrence of INH-R TB and its major impact on 5 outcomes, there has been remarkably little research on therapy for INH-R TB. Hence, the 6 optimal regimen for INH-R TB, including use of fluoroquinolones and duration of 7 treatment remains controversial. 8
This IPD meta-analysis was built upon a recent systematic review and aggregate data meta-9 analysis (Gegia el at., Lancet Infect Dis. 2017; 17(2):223-34), in which four electronic 10 databases (Cochrane database of systematic reviews and randomized trials, PubMed, 11
Embase and HealthStar) were searched with the terms "Tuberculosis" AND "treatment" 12 OR "therapy" AND "INH" OR "isoniazid resistance" up to March 2015. This review 13
found that treatment of patients with unrecognized INH-R TB with the standard regimen 14 recommended for newly diagnosed patients would result in combined failure and relapse 15 rates of 12%, and 8% would acquire rifampin resistance. All studies included in this 16 review were considered eligible for the IPD meta-analysis. We added previously excluded 17 studies that might have been suitable for individual data analysis, plus studies included in a 18 review on INH-R TB in children, and seven additional studies published after May 2015 19
identified from an updated search finalized on February 10th 2016, using the same search 20 terms and databases as the original review. In addition, five of the contacted authors 21 provided other unpublished datasets (three now published) and three regional or national 22 surveillance datasets were provided by authors responding to an invitation to all 23 participants at a WHO European regional Resistant TB surveillance meeting. 24 25
Added value of this study: 26 Subject-level data were compiled from 33 studies and a total of 3923 patients from 23 of 27 these studies (21 cohorts and 2 randomized clinical trials), received one of the regimens of 28 interest. Bias was assessed by using an eight items scale: sampling method and outcome 29 definition were critical and six were important criteria (participation rate, attrition rate and 30 completeness of information for age, HIV status, cavity at chest-x ray and smear). Based on 31 these criteria, the quality was judged low in one study, moderate in four, and high in the 32 remainder. 33
Compared to 6 months of rifampin, ethambutol and pyrazinamide (REZ), longer duration 34 of REZ did not results in significantly improved treatment success or less acquired drug 35 resistance. Addition of a fluoroquinolone to a core regimen of at least 6 months of REZ, 36 was associated with improved success, and less acquired drug resistance, but no difference 37 in mortality. Adding an FQ to a regimen with 2-3 months Z, and 6 or more months of R&E, 38 resulted in somewhat, but not significantly, better odds of success. The retreatment regimen 39
(SM added to 6 months of RE and 1-3 months of Z) was associated with significantly 40 worse success, compared to at least 6 months REZ. 41 42
Implications of all the available evidence: 43
Findings of this study emphasize the importance of detecting INH resistance and support 44 the use of FQ in addition to a core regimen of 6 months of REZ. The addition of isoniazid, 45 and prolongation of REZ beyond 6 months appear to provide no benefits for this condition.
46
Our results support a move away from use of the streptomycin-containing previously 47 recommended retreatment regimen. Because of the observational nature of the data, these 48 results are graded very low quality evidence; hence these results are insufficient to support 1 strong treatment recommendations. But they do support the conduct of randomized trials to 2 define the optimal treatment of this common and overlooked condition -particularly to 3 assess the optimal type and duration of FQ and optimal duration of pyrazinamide. patents missing information for these variables: past TB treatment: 8%; AFB smear: 2%; HIV 8%, polyresistance, age and sex: 0%. HIV status was missing, but assumed to be negative 10 in 3 studies (n =720 patients) in settings where the prevalence of HIV co-infection rate in patients with active TB was <5% based on WHO surveillance data. 11 c) N treated is less than in success analysis because patients with fail/relapse but no acquired drug resistance or with non-rifampin acquired resistances were excluded from this analysis. 12 d) I squared estimated for the adjusted odds ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis.
24 13 e) NC: the I squared could not be calculated because the Tau squared (on which the I squared is based) was not estimated in SAS.
14 Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens SM: streptomycin; R: rifampin; Z: pyrazinamide. 15 16 17 18 fail/relapse but no acquired drug resistance or with non-rifampin acquired resistances were excluded from this analysis. c) Number of pairs used in propensity score matched analysis.
5
For example 248 persons who received (H)REZFQ and an equal number who received the comparator were analyzed for the outcome of success; d) Estimates based on pairs matched 6 for age, sex, HIV status, past TB treatment, sputum AFB smear(positive vs negative) and resistance to other drugs besides ISONIAZID, if used. Percentage of patents missing 7 information for these variables: past TB treatment: 8%; AFB smear: 8%; HIV 8%, polyresistance, age and sex: 0%. HIV was missing, but assumed to be negative in 3 studies (n=1164 patients) in settings where the prevalence of HIV coinfection rate in patients with active TB was <5%, based on WHO surveillance data. e) I squared estimated for the adjusted odds 1 ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis 24 NC:the I squared could not be calculated 2 because the Tau squared (on which the I squared is based) was not estimated in SAS. f) this is an unadjusted I squared value, adjusted could not be calculated 3 4
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens SM: streptomycin; R: rifampin; Z: pyrazinamide; 5 FQ: Fluoroquinolone.
